Although there are a number of vaccines available for influenza it is widely recognised there is a desperate need for new ones, see WHO report here and CDC site here
And in particular better vaccines are needed for more vulnerable groups, see link here

There is now increasing interest and growing evidence to support respiratory routes of vaccination. For example, ongoing Phase 1 clinical trials are looking at the efficacy of the Oxford/Astra-Zeneca SARS-CoV-2 vaccine when delivered via the inhalational route. However, our technology has the advantage of low-dose vaccination which is inherently more boostable, more cost-effective, quicker to manufacture therefore more suitable for the logistical challenges of the developing world and less likely to induce unwanted side-effects.

Our approach provides cross protection against related strains and potentially many advantages over other vaccines in development, see WHO link above.